Drug Safety Surveillance Based On Medicare Data Should Top List Of FDA Priorities
This article was originally published in The Pink Sheet Daily
Executive Summary
Implementation of the Medicare drug benefit provides an opportunity for an active surveillance system to collect drug safety data, Drug Safety & Risk Management Advisory Committee members say. Active surveillance can act as a safety net for FDA's adverse events signaling system.